Article

Online CME: Do You Know Who I Am? A Look at the Devastating Effects of Alzheimer's Disease - Strategies for Early Recognition and Treatment

Earn 1.00 AMA credit by participating in this free online CME activity.

Credits: 1.00

Fee: None

Expires: March 9, 2011

Multimedia: None

With the goal of providing “clinicians with an overview of emerging therapies, strategies for early recognition, and effective management of patients with Alzheimer’s disease (AD),” this program thoroughly reviews risk factors associated with AD onset, and strategies for disease prevention and brain health maintenance. Participants will also learn about clinical tools for identifying and assessing AD so that patients can receive early intervention and treatment, as well as available guidelines and quality measure that can be incorporated into one’s practice.

Click here to access this third-party resource.

More Online, Alzheimer's-focused CME Activities:

  • Exploring the Potential of Novel Mechanisms in the Treatment of Alzheimer's and Huntington's Diseases
  • Improving the Quality of Patient Screening, Timely Diagnosis, and Institution of Therapy for Alzheimer’s Disease Among Minority Populations in the Community and Long-term Care Settings
  • Mitochondria: An Emerging Therapeutic Focus in Alzheimer’s Disease Therapy (copy the title into the search window, and choose your profession to access this activity)
Related Videos
Parent Stress Reduces Over Time When Weaning Child Off Tube Feeding with Hide Okuno, MS
Akif Shameem, MD: Generalized Anxiety Disorder Linked to Longer Hospitals in Children with IBD
Jonathan Meyer, MD: Cognitive Gains, Dopamine-Free Schizophrenia Treatment with Xanomeline Trospium Chloride
Chelsie Monroe: Challenges Clinicians Should Consider When Prescribing Muscarinic Modulators for Schizophrenia
Thumbnail for schizophrenia special report around approval of Cobenfy.
Thumbnail for schizophrenia special report around approval of Cobenfy.
Thumbnail for schizophrenia special report around approval of Cobenfy.
Thumbnail for schizophrenia special report around approval of Cobenfy.
© 2024 MJH Life Sciences

All rights reserved.